Cross-sex Hormone Therapy and Neuronal Plasticity
Gender Dysphoria
About this trial
This is an interventional treatment trial for Gender Dysphoria focused on measuring Estradiol;, Brain, glutamate, spectroscopy, hypogonadism
Eligibility Criteria
Inclusion Criteria:
- Transgender women
- Age 18 to 60 years old.
Exclusion Criteria:
- Use of psychostimulant drugs
- Use of Antidepressive, Mood Stabiliser, Anti-psychotic, Benzodiazepines, anti-convulsivants, Anorexigenic
- Endocrinological disease (other than diabetes)
- Arterial Hypertensive Disease of Diabetes Mellitus out of control target
- Neurological disease, including stroke or recent cranial trauma with loss or consciousness
- HIV with low CD4 or high viral charge or symptomatic AIDS
- Neoplasia
Sites / Locations
- Hospital de Clínicas de Porto AlegreRecruiting
Arms of the Study
Arm 1
Experimental
Transgender Women
Transgender women who already completed GAS or that agreed to start gonadotropin release hormone analogue to suppress endogenous sex hormones. If the participants were using CSHT in the moment of the study assignment, they were asked to stop hormones for 30 days to evaluate the impact of hypogonadism in the brain. After this first assessment, they received prescriptions for Estradiol (equine conjugated oestrogen, or estradiol valerate, or topic 17-beta estradiol formulations) for 60 days, and the impact of CSHT was evaluated again to compare to washout condition.